Article Text

PDF
AB1078 Diagnostic Value of Serological Markers in Rheumatoid Arthritis in Patients of Kyrgyz Republic
  1. N. Omurzakova1,
  2. E. Mirrakhimov2,
  3. A. Djumagulova1
  1. 1National Center of Cardiology and Internal Medicine
  2. 2Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan

Abstract

Background Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial joints, often with a progressive and destructive course, associated with the production of wide range of autoantibodies, and their detection has diagnostic and prognostic implication.

Objectives This study was to estimate the diagnostic value of antibodies against cyclic citrullinated peptide (ACCP) and nuclear antigen RA33 of the IgA rheumatoid factor (RF) versus the value of routinely used profile of autoantibodies in diagnostic work-up of RA.

Methods We identified 230 patients with RA prehistory of varying duration. The control group was comprised of 96 patients, including patients with seronegative spondyloarthropathies (SpA), Psoriatic Arthritis (PsA) and diffuse connective tissue diseases, as well as sex and age matched healthy controls. Serum levels of IgM and IgA RF, antibodies against cyclic citrullinated peptide (ACCP), antibodies against RA33 antigen (ARA33) and antinuclear factor (ANF) were measured in all patients and controls.

Results Diagnostic sensitivity of ACCP equaled 81%, IgM RF - 76%, IgA RF - 46%, ARA33 - 36% and ANF - 29%. ACCP was significantly more commonly associated with IgM RF. Among RF seronegative patients ACCP were found in 37% cases with 26 IU/Ml detection threshold, and in 26% - with 32 IU/Ml, allowing to increase diagnostic specificity of the test up to 93% with the increment of diagnostic threshold. Incidence of ARA33 was not significantly different among the RF and ACCP positive or negative subgroups, thus making ARA33 an independent RA marker. Specificity of this marker was 83,4%, thus making it inferior to RF and ACCP by a composite of diagnostic characteristics.

Conclusions The measurement of RA33 is a rational approach at the next second stage of serologic testing work-up in suspected cases of RA onset, when initial RF and ACCP tests were negative.

References

  1. Emery P., Breedveld F.C., Dougados M. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002;61(4):290-7.

  2. Malakoutikhah M., Gomara M.J., Gomez-Puerta J.A. et al. The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis. J Med Chem 2011;54(21):7486-92.

  3. Schneeberger E., Citera G., Heredia M. et al. Clinical significance of anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol 2008;27(4):517-9.

  4. Pincus T., Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages andlimitations.Rheum Dis Clin North Am 2009;35(4):731-4.

  5. Aletaha D., Neogi T., Silman A.J. et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69(9):1580-8.

  6. Metz C.E. Basic principles of ROC analysis. Semin Nucl Med 1978;8(4):283-98.

  7. Nell V.P., Machold K.P., Stamm T.A. et al. Autoantibody profiling as early diagnostic and prognostic tool forrheumatoid arthritis. Ann Rheum Dis 2005;64(12):1731-6.

  8. Nell-DuxneunerV., Machold K., Stamm T. et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 2010;69(1):169-74.

Acknowledgements All employees of Department of Rheumatology National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyz Republic

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.